Drug Trial Radar · NCT06257264
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
103
Actual
Start
Mar 11, 2024
Primary completion
Aug 27, 2026
Study completion Aug 27, 2027
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC). The study will also identify a recommended dose for expansion (RDFE) for BG-68501 as monotherapy and in combination for subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion, including evaluation of food effect) and Part 2 (dose expansion).
Conditions
- Breast Cancer
- Small Cell Lung Cancer
- Ovarian Cancer
- Gastric Cancer
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Advanced Solid Tumor
- Endometrial Cancer
- Prostate Cancer
- TNBC - Triple-Negative Breast Cancer
- GastroEsophageal Cancer
- Bladder Cancer
Interventions
BG-68501Drug
Planned doses administered orally.
FulvestrantDrug
Standard dose administered via intramuscular injection.
BGB-43395Drug
Planned doses administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the first dose of study drug(s) to 30 days after the last dose; approximately 6-12 months
- Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501Time frame: Up to approximately 24 months
- Part 1: Recommended dose(s) for Expansion (RDFE) of BG-68501 monotherapy in participants with solid tumorsTime frame: Up to approximately 24 months
- Part 1: RDFE of BG-68501 in combination with fulvestrant and BGB-43395 in participants with HR+/HER2- BCTime frame: Up to approximately 24 months
- Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 20 months
Locations
24 sites in 6 countries. Site status is shown where the registry gives one.
Hoag Memorial Presbyterian
Newport Beach, California
Florida Cancer Specialists and Research Institute
Lake Mary, Florida
Washington University School of Medicine
St Louis, Missouri
Titan Health Partners Llc Dba Astera Cancer Care
East Brunswick, New Jersey
Avera Cancer Institute
Sioux Falls, South Dakota
Mary Crowley Cancer Research
Dallas, Texas
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
Saint Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
Genesiscare North Shore
St Leonards, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Cancer Research South Australia
Adelaide, South Australia, Australia
Monash Health
Clayton, Victoria, Australia
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shengjing Hospital of China Medical Universityhuaxiang Branch
Shenyang, Liaoning, China
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
Rambam Health Care Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
The Institute of Oncology, Arensia Exploratory Medicine
Chisinau, Moldova
Auckland City Hospital
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.